Each company’s board of directors approved the acquisition.
The FDA approved Tavneos, the brand name for the generic avacopan, in October 2021, to be an additional treatment for adult patients with a severe, rare condition in which the immune system attacks blood vessels. In a clinical trial, Tavneos had a 65.7 remission rate among study participants.
The oral drug is “a transformative, first-in-class treatment for ANCA-associated vasculitis,” Robert Bradway, Amgen’s CEO and chairman, stated in the news release.
Mr. Bradway said he was excited about the Taveneos launch and helping more patients with the sometimes life-threatening immune system disease.
Active-neutrophil cytoplasmic autoantibody-associated vasculitis affects about 200 million people, according to the FDA.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
